What kind of uptake can Gilead expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) injection ...

The US Food and Drug Administration (FDA) has approved Gilead Science’s Yeztugo for the prevention of human immunodeficiency ...

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...